| EMA number | EMEA/H/C/002560 |
| ATC code | N07XX59 |
| Authorisation | 24 June 2013 |
| Withdrawn | 15 February 2016 |
| Revision | 2 |
Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.